Daiichi Sankyo and Kite have now agreed that the Marketing Authorization for Yescarta will be transferred to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc., in 2023.

BASKING RIDGE, N.J., Oct. 4, 2017 /PRNewswire/ -- Daiichi Sankyo, Inc. today announced the establishment of Commitments in Pain Care, a program focused on education and awareness about responsible ...

To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch. Please see accompanying full Prescribing Information, ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it failed to prolong the lives of patients in a late-stage study, the ...

Daiichi Sankyo's company logo is pictured at its headquarters in Tokyo, Japan, October 20, 2023. REUTERS/Kim Kyung-Hoon/File Photo Purchase Licensing Rights, opens new tab.